AI assistant
Camlin Fine Sciences Ltd — Investor Presentation 2021
Nov 12, 2021
59255_rns_2021-11-12_80a53799-d24a-4f67-98e9-b3831d8f8432.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [100 x 31] intentionally omitted <==
12[th] November, 2021
||To,
BSE Limited,
25, P. J. Towers,
Dalal Street,
Mumbai – 400 001
Ref:Company Scrip Code: 532834|To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai‐ 400051
Ref:Symbol:CAMLINFINE || Series: EQ|
|---|---|---|
Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ‐ (“SEBI LODR”)
This is in continuation to our disclosure dated November 11, 2021 in relation to the conference call with various domestic and international investors and analysts organized by ICICI Securities to discuss the financial results of the Company for the quarter and half year ended September 30, 2021 on November 12, 2021, please find enclosed herewith the earnings presentation to be made for the aforesaid call.
It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the earnings presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.
We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.
Thanking You, Encl.: a/a. For Camlin Fine Sciences Limited
==> picture [55 x 53] intentionally omitted <==
==> picture [106 x 51] intentionally omitted <==
_______ Santosh Parab Chief Financial Officer
==> picture [426 x 57] intentionally omitted <==
EARNINGS PRESENTATION
H1 / Q2-FY22
Sna shot p
==> picture [69 x 30] intentionally omitted <==
==> picture [55 x 55] intentionally omitted <==
==> picture [55 x 55] intentionally omitted <==
==> picture [55 x 55] intentionally omitted <==
==> picture [54 x 55] intentionally omitted <==
One of the few end-to-end Strong management team with Global experience with local 5 Manufacturing Facilities integrated specialty chemicals experienced industry professionals presence 2 R&D Centres company 5 Application Labs Diversified product basket of over Established customer base of over One of the largest global Strong operational efficiency with the 100 products catering to several 1,000 customers across 80 countries Antioxidant and Vanillin Diphenol facilities established at industries manufacturers Dahej, Gujarat Entered into preferred supplier 10-year CAGR Strategically expanding into high Proven track record of inorganic agreement with Lockheed Martin Revenue: 23.71% margin products like Blends and acquisitions and turnarounds Advanced Energy Storage to supply PAT: 50.72% Vanillin a specialty chemical CFO: 59.79%
2
About the Company
-
Camlin Fine Sciences Limited (CFS) was formed in 2006 after de-merging the fine chemical business from Camlin Ltd and got listed on the BSE and NSE in 2007 and 2011, respectively.
-
It is a vertically integrated company, engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors such as – Food, feed, animal and pet nutrition, Pharma, Petrochemicals, Polymers, Flavours & Gragrance, Agrochemicals, Dyes & Pigments, and Bio Diesel.
-
CFS has subsidiaries in Mexico, North America, China, Europe and Brazil with Manufacturing Facilities in India, Brazil, China, Mexico and Italy, R&D Centres at Tarapur (India) and Ravenna (Italy) and Application Labs in India, Brazil, North America, Italy and Mexico
-
CFS markets its products to over 80 countries in Europe, Asia Pacific (including India), North Africa, Middle East, South, Central and North America.
FY21 Business Mix (Revenue Share %)
-
Shelf Life Solutions (53%) : Includes Anti-oxidants, Blends and Additives
-
Performance Chemicals (29%): Includes Specialty Chemicals
-
Aroma Chemicals (17%): Includes Vanillin and Ethyl Vanillin
-
Health and Wellness: Includes nutraceuticals
==> picture [69 x 30] intentionally omitted <==
Total Operational Revenue (INR Mn)
==> picture [183 x 112] intentionally omitted <==
----- Start of picture text -----
11,871
10,491
8,922
7,228
6,420
5,469
FY17 FY18 FY19 FY20 FY21 H1-FY22
----- End of picture text -----
H1-FY22 Operational Revenue Breakup
==> picture [202 x 137] intentionally omitted <==
----- Start of picture text -----
Others,
Aroma
1%
2%
Performance
Shelf-life
Chemicals
Extension
44%
25%
Blends
29%
----- End of picture text -----
3
H1 / Q2-FY22 FINANCIAL OVERVIEW
H1 / Q2-FY22 Financial Highlights
==> picture [69 x 30] intentionally omitted <==
Q2 FY22 Financial Highlights (Consolidated): Q2 FY22 Financial Highlights (Standalone):
INR 3,112 Mn INR 227 Mn INR 277 Mn INR (39) Mn INR 1,382 Mn INR 29 Mn INR 39 Mn INR (70) Mn Total Revenue EBITDA Adjusted EBITDA PAT Total Revenue EBITDA Adjusted EBITDA PAT
7.30% 8.92% (1.25)% EBITDA Margin Adjusted EBITDA PAT Margin Margin
2.13% 2.82% (5.06)% EBITDA Margin Adjusted EBITDA PAT Margin Margin
H1-FY22 Financial Highlights (Consolidated):
H1-FY22 Financial Highlights (Standalone):
INR 6,420 Mn INR 733 Mn INR 733 Mn INR 199 Mn INR 2,839 Mn INR 231 Mn INR 231 Mn INR (23) Mn Total Revenue EBITDA Adjusted EBITDA PAT Total Revenue EBITDA Adjusted EBITDA PAT
11.42% 11.42% 3.10% EBITDA Margin Adjusted EBITDA PAT Margin Margin
8.13% 8.13%
8.13% 8.13% (0.80)% EBITDA Margin Adjusted EBITDA PAT Margin Margin
5
* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)
H1 / Q2-FY22 Operational Highlights (Consolidated)
==> picture [69 x 30] intentionally omitted <==
- Demand remained strong however reduction in turnover can be primarily attributed to tepid performance of CFS India
One time impacts
-
Loss of production compared to Q1-FY22
-
Due to disruptions in logistics & supply chain
-
Technical issues in scale up of Diphenol Plant at Dahej to attain 100% capacity
-
Consequent impact on production of high volume / high margin products such as TBHQ, BHA, MEHQ & PDMB compared to Q1-FY22 leading to reduction in sale of INR 25 Cr & margin of approx. INR 12.5 Cr
-
Consequent impact on product mix
-
Non-recurring expenditures amounted to INR 3.50 Cr in the quarter
-
Foreign exchange loss in the quarter of INR 5.03 Cr compared to gain of INR 9.63 Cr in Q1-FY22
Structural & Other Impacts
-
Unprecedented increase in logistic cost during the quarter which could not be passed on immediately – recovered with lag of a quarter – mitigation by way of changing terms to FOB from October 2021 wherever possible
-
Inflationary trend continues in crude impacting the raw material costs
-
Increase in employee costs of INR 1.80 Cr – yearly increment & induction of managing director & sales personnel and new business heads in the current quarter – benefits of new inductees will start fructifying in subsequent quarters
-
Gross Margins remained stable QoQ, however shy of expected 50%+ margin as increase in selling prices were undone by inflationary conditions and a lag of quarter to pass to the customer
6
Q2-FY22 Standalone Income Statement (Ind-AS)
==> picture [69 x 30] intentionally omitted <==
| Income Statement (Mn) | Q2-FY22 | Q1-FY22 | Q-o-Q | Q2-FY21 | Y-o-Y |
|---|---|---|---|---|---|
| Operational Revenue | 1,382 | 1,457 | (5.2)% | 1,468 | (5.9)% |
| Total Expenses | 1,352 | 1,265 | 6.9% | 1,397 | (3.2)% |
| Operational EBITDA | 29 | 192 | (84.9)% | 71 | (59.2)% |
| Operational EBITDA Margins(%) | 2.13% | 13.18% | NA | 4.84% | (271) Bps |
| Adjusted EBITDA* | 39 | 192 | (79.7)% | 144 | (73.0)% |
| Adjusted EBITDA Margins(%) | 2.82% | 13.18% | NA | 9.81% | (699) Bps |
| Other Income | 10 | 38 | (73.7)% | 13 | (23.1)% |
| Depreciation | 66 | 64 | 3.1% | 34 | 94.1% |
| Finance Cost | 75 | 96 | (21.9)% | 59 | 27.1% |
| PBT | (101) | 70 | NA | (9) | NA |
| Tax | (32) | 22 | NA | 1 | NA |
| Profit After tax | (70) | 47 | NA | (10) | NA |
| PAT Margins(%) | NA | 3.23% | NA | NA | NA |
| Other Comprehensive Income | (2) | 1 | NA | (1) | NA |
| Total Comprehensive Income | (72) | 48 | NA | (11) | NA |
| Diluted EPS(INR) | (0.46) | 0.31 | NA | (0.08) | NA |
* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)
7
H1-FY22 Standalone Income Statement (Ind-AS)
==> picture [69 x 30] intentionally omitted <==
| Income Statement (Mn) | H1-FY22 | H1-FY21 | Y-o-Y |
|---|---|---|---|
| Operational Revenue | 2,839 | 2,679 | 6.0% |
| Total Expenses | 2,608 | 2,446 | 6.6% |
| Operational EBITDA | 231 | 233 | (0.9)% |
| Operational EBITDA Margins(%) | 8.13% | 8.70% | (57) Bps |
| Adjusted EBITDA* | 231 | 302 | (23.6)% |
| Adjusted EBITDA Margins(%) | 8.13% | 11.27% | (314) Bps |
| Other Income | 39 | 23 | 69.5% |
| Depreciation | 131 | 64 | 104.1% |
| Finance Cost | 171 | 145 | 17.9% |
| Exceptional Items | - | 5 | NA |
| PBT | (32) | 42 | NA |
| Tax | (9) | 14 | NA |
| Profit After tax | (23) | 28 | NA |
| PAT Margins(%) | NA | 1.05% | NA |
| Other Comprehensive Income | (1) | (1) | NA |
| Total Comprehensive Income | (24) | 27 | NA |
| Diluted EPS(INR) | (0.15) | 0.22 | NA |
Q2-FY22 Consolidated Income Statement (Ind-AS)
==> picture [69 x 30] intentionally omitted <==
| Income Statement (INR Mn) | Q2-FY22 | Q1-FY22 | Q-o-Q | Q2-FY21 | Y-o-Y |
|---|---|---|---|---|---|
| Operational Revenue | 3,112 | 3,308 | (5.9)% | 2,568 | 21.2% |
| Total Expenses | 2,885 | 2,852 | 1.2% | 2,232 | 29.3% |
| Operational EBITDA | 227 | 456 | (50.2)% | 336 | (32.4)% |
| Operational EBITDA Margins(%) | 7.30% | 13.78% | (648) Bps | 13.08% | (578) Bps |
| Adjusted EBITDA* | 277 | 456 | (39.3)% | 425 | (34.8)% |
| Adjusted EBITDA Margins(%) | 8.92% | 13.78% | (486) Bps | 16.55% | (763) Bps |
| Other Income | 6 | 105 | (94.3)% | 13 | (53.8)% |
| Depreciation | 134 | 134 | NA | 96 | 39.6% |
| Finance Cost | 91 | 101 | (9.9)% | 81 | 12.3% |
| Share ofprofit/ loss of associate | (1) | - | NA | - | NA |
| PBT | 8 | 326 | (97.5)% | 172 | (95.3)% |
| Tax | 46 | 88 | (47.7)% | 75 | (38.7)% |
| Profit After Tax | (39) | 238 | NA | 97 | NA |
| PAT Margins(%) | NA | 7.19% | NA | 3.78% | NA |
| Other Comprehensive Income | (62) | 34 | NA | 42 | NA |
| Total Comprehensive Income | (101) | 272 | NA | 139 | NA |
| Diluted EPS(INR) | (0.37) | 1.48 | NA | 0.46 | NA |
* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)
9
H1-FY22 Consolidated Income Statement (Ind-AS)
==> picture [69 x 30] intentionally omitted <==
| Income Statement (INR Mn) | H1-FY22 | H1-FY21 | Y-o-Y |
|---|---|---|---|
| Operational Revenue | 6,420 | 5,626 | 13.6% |
| Total Expenses | 5,687 | 4,778 | 19.0% |
| Operational EBITDA | 733 | 848 | (13.5)% |
| Operational EBITDA Margins(%) | 11.42% | 15.07% | (365) Bps |
| Adjusted EBITDA* | 733 | 968 | (24.3)% |
| Adjusted EBITDA Margins(%) | 11.42% | 17.21% | (579) Bps |
| Other Income | 61 | 17 | NA |
| Depreciation | 268 | 191 | 40.3% |
| Finance Cost | 192 | 187 | 2.7% |
| Share ofprofit/ loss of associate | (2) | - | NA |
| PBT | 333 | 487 | (31.6)% |
| Tax | 134 | 185 | (27.6)% |
| Profit After Tax | 199 | 302 | (34.1)% |
| PAT Margins(%) | 3.10% | 5.37% | (227) Bps |
| Other Comprehensive Income | (28) | 89 | NA |
| Total Comprehensive Income | 171 | 391 | (56.3)% |
| Diluted EPS(INR) | 1.11 | 1.64 | (32.3)% |
| 0 * EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss) |
10
COUNTRY OVERVIEW
Country Wise Quarterly Performance
==> picture [69 x 30] intentionally omitted <==
==> picture [673 x 182] intentionally omitted <==
----- Start of picture text -----
CFS India CFS Mexico CFS Europe
1,468 1,457 1,117
1,382
1,060
751 762 951
607
Q2-FY21 Q1-FY22 Q2-FY22 Q2-FY21 Q1-FY22 Q2-FY22 Q2-FY21 Q1-FY22 Q2-FY22
----- End of picture text -----
==> picture [455 x 161] intentionally omitted <==
----- Start of picture text -----
CFS Brazil CFS Wanglong
203 197
159
309
- -
Q2-FY21 Q1-FY22 Q2-FY22 Q2-FY21 Q1-FY22 Q2-FY22
----- End of picture text -----
CFS North America
==> picture [156 x 124] intentionally omitted <==
----- Start of picture text -----
167
121
97
Q2-FY21 Q1-FY22 Q2-FY22
----- End of picture text -----
12
Countr Wise Yearl Performance y y
==> picture [69 x 30] intentionally omitted <==
==> picture [706 x 352] intentionally omitted <==
----- Start of picture text -----
CFS India CFS Mexico CFS Europe
3,762
2,735
5,798 6,000 2,571 3,296
5,481 3,091
2,172 2,771
4,050 1,642 2,177
1,513
2,839
FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22
CFS Brazil CFS Wanglong CFS North America
1,765 1,817 500
717
386
618
1,345 400 334
288
411 400 300 236
178
252 200
100
-
-
FY18 FY19 FY20 FY21 H1-FY22 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22
(INR Mn)
Operational Revenue
(INR Mn)
Operational Revenue
----- End of picture text -----
13
HISTORICAL FINANCIAL OVERVIEW
Historical Standalone Income Statement
==> picture [69 x 30] intentionally omitted <==
| Particulars (INR Mn) | FY19 | FY20 | FY21 | H1-FY22 |
|---|---|---|---|---|
| Operational Income | 5,481 | 5,798 | 6,000 | 2,839 |
| Total Expenses | 5,182 | 5,201 | 5,382 | 2,608 |
| EBITDA | 299 | 597 | 618 | 231 |
| EBITDA Margin | 5.46% | 10.30% | 10.30% | 8.13% |
| Depreciation | 91 | 113 | 193 | 131 |
| Finance Cost | 203 | 281 | 325 | 171 |
| Other Income | 137 | 241 | 55 | 39 |
| Exceptional Items | - | 31 | 5 | - |
| PBT | 142 | 413 | 150 | (32) |
| Tax | 35 | 106 | 67 | (9) |
| Profit After Tax | 107 | 307 | 83 | (23) |
| PAT Margin | 1.95% | 5.29% | 1.38% | NA |
| Other Comprehensive Income | (3) | (3) | (4) | (1) |
| Total Comprehensive Income | 104 | 304 | 79 | (24) |
| Diluted EPS (INR per share) | 0.88 | 2.53 | 0.6 | (0.15) |
15
Standalone Balance Sheet
==> picture [69 x 30] intentionally omitted <==
| Particulars (INR Mn) | FY20 | FY21 | H1- FY22 |
Particulars (INR Mn) | FY20 | FY21 | H1- FY22 |
||
|---|---|---|---|---|---|---|---|---|---|
| EQUITY | 3,768 | 4,646 | 5,064 | Non-Current Assets | 3,802 | 4,087 | 4,826 | ||
| a)EquityShare Capital | 121 | 127 | 128 | a)Property,Plant and Equipment | 686 | 2,457 | 2,428 | ||
| b)Other Equity | 3,647 | 4,519 | 4,936 | b)Capital Work In Progress | 1,742 | 184 | 706 | ||
| c)Right-Of-UseAssets | 246 | 227 | 271 | ||||||
| c)Non-ControllingInterest | - | - | |||||||
| d)Investment Property | 21 | 21 | 21 | ||||||
| LIABILITIES | 1,240 | 1,763 | 2,019 | ||||||
| e)Other Intangible Assets | 4 | 232 | 221 | ||||||
| Non-Current Liabilities | |||||||||
| f)Intangible Assets under Development | 240 | - | - | ||||||
| Financial Liabilities | |||||||||
| g) Financial Assets | |||||||||
| a)Borrowings | 1,130 | 1,627 | 1,859 | (i)Investments |
740 | 736 | 762 | ||
| b)Lease Liabilities | 50 | 41 | 61 | (ii)Loans | 36 | 31 | 36 | ||
| c)Provisions | 28 | 28 | 35 | (iii)Other Financial Assets | - | 1 | - | ||
| d)Deferred Tax Liabilities(Net) | 21 | 63 | 60 | h)Deferred tax assets(Net) | - | - | - | ||
| i)Income Tax Assets | 33 | 44 | 48 | ||||||
| e)Other Non-Current Liabilities | 11 | 4 | 4 | ||||||
| j)Other Non-Current assets | 54 | 154 | 333 | ||||||
| Current Liabilities | 3,905 | 4,258 | 3,922 | ||||||
| Current Assets | 5,112 | 6,580 | 6,180 | ||||||
| a)Financial Liabilities | |||||||||
| a)Inventories | 972 | 1,314 | 1,400 | ||||||
| (i)Borrowings | 2,184 | 2,007 | 1,778 | ||||||
| b) Financial Assets | |||||||||
| (ii)Trade Payables | 1,330 | 1,929 | 1806 | (i)Investments |
- | - | |||
| (iii)Other Financial Liabilities | 250 | 216 | 154 | (ii)Trade Receivables | 3,235 | 3,682 | 3,663 | ||
| (iv)Lease Liabilities | 10 | 12 | 18 | (iii) CashandCash Equivalents | 7 | 188 | 106 | ||
| (iv)Other Bank balances | 124 | 628 | 193 | ||||||
| b)Other Current Liabilities | 61 | 83 | 154 | ||||||
| (v)Loans | 301 | 299 | 345 | ||||||
| c)Provisions | 4 | 10 | 12 | ||||||
| (vi)Other financial assets | 235 | 207 | 219 | ||||||
| d)Current Tax Liabilities(Net) | 66 | 1 | - | ||||||
| c)Other Current Assets | 237 | 262 | 254 | ||||||
| GRAND TOTAL - EQUITIES & LIABILITES |
8,913 | 10,667 | 11,005 | ||||||
| GRAND TOTAL – ASSETS | 8,913 | 10,667 | 11,005 | ||||||
~~16~~
Historical Consolidated Income Statement
==> picture [69 x 30] intentionally omitted <==
| PARTICULARS (INR Mn) | FY19 | FY20 | FY21 | H1-FY22 |
|---|---|---|---|---|
| Operational Income | 8,922 | 10,491 | 11,871 | 6,420 |
| Total Expenses | 8,235 | 9,184 | 10,052 | 5,687 |
| EBITDA | 687 | 1,307 | 1,819 | 733 |
| EBITDA Margin | 7.70% | 12.46% | 15.32% | 11.42% |
| Depreciation | 290 | 328 | 443 | 268 |
| Finance Cost | 367 | 431 | 375 | 192 |
| Other Income | 138 | 34 | 50 | 61 |
| Income from Associate | (1) | - | - | - |
| PBT | 167 | 582 | 1,051 | 333 |
| Tax | 137 | 284 | 397 | 134 |
| Profit After Tax | 30 | 298 | 654 | 199 |
| PAT Margin | 0.34% | 2.84% | 5.51% | 3.10% |
| Other Comprehensive Income | 5 | 13 | 1,135 | (28) |
| Total Comprehensive Income | 35 | 311 | 1,789 | 171 |
| Diluted EPS (INR per share) | 0.05 | 2.50 | 3.68 | 1.11 |
17
Consolidated Balance Sheet
==> picture [69 x 30] intentionally omitted <==
| PARTICULARS (INR Mn) | FY20 | FY21 | H1-FY22 | PARTICULARS (INR Mn) | FY20 | FY21 | H1-FY22 |
|---|---|---|---|---|---|---|---|
| EQUITY | 4,601 | 7,131 | 7,737 | Non-Current Assets | 5,591 | 6,869 | 7,744 |
| a)Property,Plant and Equipment | 2,034 | 4,818 | 4,753 | ||||
| a)EquityShare Capital | 121 | 127 | 128 | ||||
| b)Capital Work In Progress | 1,761 | 237 | 843 | ||||
| b)Other Equity | 3,910 | 6,307 | 6,885 | ||||
| c)Right-Of-Use Assets | 338 | 313 | 391 | ||||
| c)Non-ControllingInterest | 570 | 697 | 724 | ||||
| d)Investment Property | 21 | 21 | 21 | ||||
| LIABILITIES | e)Goodwill | 444 | 444 | 444 | |||
| Non-Current Liabilities | 2,261 | 2,907 | 2,980 | f)Intangible Assets | 221 | 240 | 221 |
| g)Intangible Assets under Development | 27 | 1 | 1 | ||||
| Financial Liabilities | |||||||
| h)Investment in Associate | 1 | 1 | 26 | ||||
| a)Borrowings | 2,115 | 2,732 | 2,753 | ||||
| i)Financial Assets | |||||||
| b)Lease Liabilities | 97 | 84 | 132 | (i)Investments | 72 | 72 | 72 |
| c)Provisions | 28 | 28 | 35 | (ii)Loans | 123 | 133 | 142 |
| (iii)Other Financial Assets | 0 | 1 | - | ||||
| d)Deferred Tax Liabilities(Net) | 21 | 63 | 60 | ||||
| j)Deferred tax assets(Net) | 407 | 330 | 347 | ||||
| Current Liabilities | 5,478 | 4,778 | 4,674 | ||||
| k)Income Tax Assets | 66 | 87 | 133 | ||||
| a)Financial Liabilities | |||||||
| l)Other Non-Current assets | 76 | 171 | 350 | ||||
| (i)Borrowings | 2,781 | 2,169 | 2,367 | Current Assets | 6,749 | 7,947 | 7,647 |
| (ii)Trade Payables | 1,737 | 1,584 | 1,646 | a)Inventories | 2,981 | 3,200 | 3,286 |
| b)Financial Assets | |||||||
| (iii)Lease liabilities | 33 | 37 | 50 | ||||
| (i)Investments | - | - | - | ||||
| (iii)Other Financial Liabilities | 672 | 687 | 238 | ||||
| (ii)Trade Receivables | 2,528 | 2,707 | 2,788 | ||||
| b)Other Current Liabilities | 110 | 202 | 283 | (iii)Cash and Cash Equivalents | 524 | 755 | 691 |
| c)Provisions | 79 | 96 | 89 | (iv)Other Bank balances | 124 | 628 | 193 |
| (v)Loans | 11 | 10 | 50 | ||||
| d)Current Tax Liabilities(Net) | 66 | 3 | 1 | ||||
| (vi)Other financial assets | 117 | 101 | 105 | ||||
| GRAND TOTAL - EQUITIES & LIABILITES |
12,340 | 14,816 | 15,391 | ||||
| c)Other Current Assets | 464 | 546 | 534 | ||||
| GRAND TOTAL – ASSETS | 12,340 | 14,816 | 15,391 |
18
Consolidated Financial Hi hli hts g g
==> picture [69 x 30] intentionally omitted <==
==> picture [727 x 349] intentionally omitted <==
----- Start of picture text -----
Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) Debt to EBITDA
28.44
14,000 11,871 2,100 15.32% 18.00%
16.00%
12,000 10,491 1,800
10,000 8,922 1,500 12.46% 1,819 11.42% 14.00%
12.00%
7,228
8,000 6,420 1,200 7.70% 10.00%
6,000 900 8.00%
1,307
4,000 600 1.74% 687 733 6.00%4.00% 6.38 3.75 2.69 6.99
2,000 300 2.00%
- - 126 0.00% 0
FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22
Net Debt to Equity Net Worth (INR Mn) ROE (%)
1.5
9,000 15.00%
1.3 7,737 10.16%
1.1 0.95 1.03 8,000 7,000 7,131 10.00% 7.40%
0.9 0.77 6,000 5,000 4,303 4,601 5.00% 0.81%
0.7 0.56 0.55 3,712
4,000
0.00%
0.5 3,000 FY18 FY19 FY20 FY21
0.3 2,000 -5.00%
1,000
0.1 -6.46%
- -10.00%
-0.1 FY18 FY19 FY20 FY21 H1-FY22 FY18 FY19 FY20 FY21 H1-FY22
----- End of picture text -----
19
Ca ital Markets p
==> picture [69 x 30] intentionally omitted <==
==> picture [645 x 149] intentionally omitted <==
----- Start of picture text -----
110.00%
90.00%
70.00%
50.00%
30.00%
10.00%
-10.00%Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21
-30.00%
Sensex Camlin
----- End of picture text -----
| Price Data (30th September, 2021) | INR |
|---|---|
| Face Value | 1.0 |
| Market Price | 183.2 |
| 52 Week H/L | 230.8/92.4 |
| Market Cap (Mn) | 23,370.3 |
| EquityShares Outstanding (Mn) | 127.6 |
| 1 Year AvgTradingVolume(‘000) | 851.3 |
==> picture [263 x 153] intentionally omitted <==
----- Start of picture text -----
Shareholding Pattern as on 30 [th] September, 2021
Promoters
21.61%
Public FPI
54.35% 5.01%
DII
19.03%
----- End of picture text -----
20
Disclaimer
==> picture [69 x 30] intentionally omitted <==
Camlin Fine Sciences Limited
No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Camlin Fine Science Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company ’ s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.
Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company ’ s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.
This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.
This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.
Valorem Advisors Disclaimer:
Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.
For further details, please feel free to contact our Investor Relations Representatives:
==> picture [84 x 64] intentionally omitted <==
Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903 9500 Email: [email protected]
21